Related Experiment Video
Updated: Jun 6, 2026
08:19
Solid Lipid Nanoparticles (SLNs) for Intracellular Targeting Applications
Published on: November 17, 2015
A potential new therapeutic system for glaucoma: solid lipid nanoparticles containing methazolamide.
Rui Li1, Sunmin Jiang, Dongfei Liu
1School of Pharmacy, Nanjing Medical University, 140 Hanzhong Road, Nanjing 210029, People's Republic of China.
Journal of Microencapsulation
|December 15, 2010
Summary
This study developed methazolamide (MTA)-loaded solid lipid nanoparticles (SLNs) for glaucoma treatment. MTA-SLNs demonstrated enhanced therapeutic efficacy and prolonged action compared to conventional treatments, offering a promising ocular drug delivery system.
Area of Science:
- Ophthalmology
- Nanotechnology
- Pharmaceutics
Background:
- Systemic administration of methazolamide (MTA) for glaucoma presents challenges, including side effects and inadequate ocular concentrations.
- Current treatments may not provide optimal therapeutic levels within the eye.
Purpose of the Study:
- To formulate methazolamide-loaded solid lipid nanoparticles (MTA-SLNs).
- To evaluate MTA-SLNs as a novel therapeutic system for glaucoma.
- To assess the physicochemical properties, pharmacodynamics, and ocular irritation of MTA-SLNs.
Main Methods:
- MTA-SLNs were prepared using a modified emulsion-solvent evaporation technique.
- Physicochemical characteristics, pharmacodynamic effects (intraocular pressure reduction), and ocular irritation (Draize test) were evaluated.
Main Results:
- MTA-SLNs exhibited a burst release but demonstrated superior therapeutic efficacy compared to drug solution and commercial products.
- The nanoparticles showed a later onset of maximum action and a more prolonged therapeutic effect.
- Ocular irritation studies were conducted to assess safety.
Conclusions:
- MTA-SLNs represent a potential ocular drug delivery carrier for glaucoma.
- This formulation offers advantages such as intensive treatment, reduced dosage, and improved patient compliance over conventional eye drops.
Related Concept Videos
01:27Open Angle Glaucoma: Treatment
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
01:23Ophthalmic Drug Delivery Systems
Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...
01:28Angle Closure Glaucoma: Treatment
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
01:25Glaucoma: Overview
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
01:22Drug Delivery: Miscellaneous Routes
Drug delivery methods like oral inhalation, nasal sprays, transdermal patches, eye drops, intravitreal injection, and rectal administration provide localized effects with reduced toxicity.
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs through the...
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs through the...
01:26Oral Drug Delivery Systems: Continuous-Release Systems
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...